clinical trial · NCT05777993
A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study
Pyruvate Kinase DeficiencyAnemia, HemolyticMitapivat
brief summary
The purpose of this study is to provide continued access to mitapivat for participants who completed an Agios-sponsored mitapivat study (antecedent) and do not have commercial access to mitapivat.
started
Jul 6, 2023
primary completion
Aug 1, 2029
completion
Aug 1, 2029
last updated
Mar 30, 2026
detailed description
Participants will continue the mitapivat dose regimen that they were receiving at the final visit of their antecedent study.
official title
A Rollover Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol